This newsletter presents you the following key sessions:
1. Video-interview with Prof. Philippe Collard, Md, PhD on latest advances in the targeted treatment
of patients with non-small cell lung cancer
2. Adding capecitabine to maintenance bevacizumab delays progression and prolongs survival in women
with HER2-negative metastatic breast cancer
3. Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS
analyses in untreated metastatic adenocarcinoma of the colon or rectum
4. Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared
to erlotinib in patients with advanced squamous cell carcinoma of the lung
5. Breast cancer treatment with everolimus and exemestane for ER-positive women: the 2nd interim
analysis of the BRAWO trial
6. Second-line afatinib significantly improves progression-free survival in recurrent or metastatic head
and neck cancer